Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis – MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen – –...
Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants VANCOUVER, Nov. 7, 2019 /CNW/ – Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and...
Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Median Progression Free Survival (mPFS) of 46 Weeks for the Second-Line...
PRINCIPIA ANNOUNCES POSITIVE PRELIMINARY DATA OF PRN1008 FOR IMMUNE THROMBOCYTOPENIA IN ONGOING PHASE 1/2 TRIAL Preliminary results from trial have been accepted as an oral presentation at upcoming American Society of Hematology Annual Meeting SOUTH SAN FRANCISCO,...
PRINCIPIA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) — Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated...
PRINCIPIA ANNOUNCES POSITIVE PRELIMINARY DATA OF PRN1008 FROM ITS ONGOING PHASE 2 PART B TRIAL IN PEMPHIGUS Consistent efficacy and safety profile for pemphigus patients observed Confirms 400mg twice daily dose in Phase 3 trial Principia to host investor conference...
Recent Comments